These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21115551)

  • 1. A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study.
    van der Kooi E; Klarenbeek NB; Güler-Yüksel M; Kerstens PJ; van der Lubbe PA; Westedt ML; ten Wolde S; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2011 Jan; 70(1):168-71. PubMed ID: 21115551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study.
    Allaart CF; Breedveld FC; Dijkmans BA
    J Rheumatol Suppl; 2007 Nov; 80():25-33. PubMed ID: 17985420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.
    Tanaka E; Mannalithara A; Inoue E; Hara M; Tomatsu T; Kamatani N; Singh G; Yamanaka H
    Ann Rheum Dis; 2008 Aug; 67(8):1153-8. PubMed ID: 17971459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial.
    Symmons D; Tricker K; Harrison M; Roberts C; Davis M; Dawes P; Hassell A; Knight S; Mulherin D; Scott DL;
    Rheumatology (Oxford); 2006 May; 45(5):558-65. PubMed ID: 16263778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What factors influence functional ability in patients with rheumatoid arthritis. Do they alter over time?
    Plant MJ; O'Sullivan MM; Lewis PA; Camilleri JP; Coles EC; Jessop JD
    Rheumatology (Oxford); 2005 Sep; 44(9):1181-5. PubMed ID: 15972357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
    Verschueren P; Esselens G; Westhovens R
    Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes.
    Wolfe F; Michaud K; Pincus T; Furst D; Keystone E
    Arthritis Rheum; 2005 Dec; 52(12):3873-9. PubMed ID: 16320335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.
    Tiippana-Kinnunen T; Paimela L; Kautiainen H; Laasonen L; Leirisalo-Repo M
    Scand J Rheumatol; 2010; 39(1):12-8. PubMed ID: 20132065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials.
    Smolen JS; Aletaha D; Grisar JC; Stamm TA; Sharp JT
    Ann Rheum Dis; 2010 Jun; 69(6):1058-64. PubMed ID: 19717399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007?
    Yazici Y; Abramson SB
    Bull NYU Hosp Jt Dis; 2007; 65(4):300-5. PubMed ID: 18081549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis.
    Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Kerstens PJ; Nielen MM; Vos K; van Schaardenburg D; Speyer I; Seys PE; Breedveld FC; Allaart CF; Dijkmans BA
    Ann Rheum Dis; 2010 Jan; 69(1):65-9. PubMed ID: 19155234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial.
    Klarenbeek NB; van der Kooij SM; Huizinga TJ; Goekoop-Ruiterman YP; Hulsmans HM; van Krugten MV; Speyer I; de Vries-Bouwstra JK; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2010 Jul; 69(7):1342-5. PubMed ID: 20472597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose chemotherapy and hematopoietic stem cell transplantation: a study of treatment preference in patients with rheumatoid arthritis and rheumatologists.
    Verburg RJ; Mahabali SD; Stiggelbout AM; Sont JK; van Laar JM
    J Rheumatol; 2002 Aug; 29(8):1653-8. PubMed ID: 12180724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.
    Baumgartner SW; Fleischmann RM; Moreland LW; Schiff MH; Markenson J; Whitmore JB
    J Rheumatol; 2004 Aug; 31(8):1532-7. PubMed ID: 15290731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
    Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I; Carmona L; Balsa A; Sanmarti R; Belmonte MA; Tena X;
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E; Freundlich B; Schiff M; Li J; Hooper M
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.